Results 111 to 120 of about 51,702 (211)

El oratorio y la casa de Astasio de Bracamonte en el Partal de la Alhambra [PDF]

, 1945
El oratorio y la casa de Astasio de Bracamonte en el Partal de la ...
Torres Balbás, Leopoldo
core   +1 more source

Recurrent disability progression endpoints in multiple sclerosis clinical trials. [PDF]

Mult Scler, 2023
Bühler A, Wolbers M, Model F, Wang Q, Belachew S, Manfrini M, Lorscheider J, Kappos L, Beyersmann J.   +8 more
europepmc   +1 more source

Voix naturelle, voix dénaturée, voix maîtrisée 

Sillages Critiques, 2005
Pierre Dubois
doaj   +1 more source

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2023
Hauser SL, Bar-Or A, Weber MS, Kletzl H, Günther A, Manfrini M, Model F, Mercier F, Petry C, Wing Q, Koendgen H, Smith T, Kappos L.   +12 more
europepmc   +1 more source

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers. [PDF]

Neurotherapeutics, 2022
Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA.   +4 more
europepmc   +1 more source

Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials. [PDF]

Sci Rep, 2023
Loomis SJ, Sadhu N, Fisher E, Gafson AR, Huang Y, Yang C, Hughes EE, Marshall E, Herman A, John S, Runz H, Jia X, Bhangale T, Bronson PG.   +13 more
europepmc   +1 more source

First Performance Review: Milton Keynes, Hugh Wood’s 'Violin Concerto No. 2'. [PDF]

, 2009
Venn, Edward
core   +1 more source

Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand. [PDF]

Pharmacoeconomics
Milne RJ, Schousboe C, Campbell JA, Mottershead J.   +3 more
europepmc   +1 more source

Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials. [PDF]

Neurology
Kappos L, Yiu S, Dahlke F, Coetzee T, Cutter GR, Yuen S, Bonati U, Lublin FD.   +7 more
europepmc   +1 more source

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. [PDF]

Mult Scler, 2022
Arnold DL, Sprenger T, Bar-Or A, Wolinsky JS, Kappos L, Kolind S, Bonati U, Magon S, van Beek J, Koendgen H, Bortolami O, Bernasconi C, Gaetano L, Traboulsee A.   +13 more
europepmc   +1 more source